||MA242 is a nuclear factor of activated T cells 1 (NFAT1) for Pancreatic Cancer Therapy and dual inhibitor of murine double minute 2 (MDM2).
||MD-224 is a highly potent and efficacious MDM2 degrader based on the proteolysistargeting chimera (PROTAC) concept,and as a new class of anticancer agent.
||MG-277 is a molecular glue compound transformed from PROTAC degradation agent, MG-277 potently inhibits tumor cell growth in a p53-independent manner.
||MI-1061 is a orally bioavailable inhibitor of MDM2 (MDM2-p53 interaction) (IC50=4.4 nM).
||Milademetan is a specific and oral inhibitor of MDM2.
||AM-8735 is an inhibitor of MDM2 ( IC50: 25 nM).
||BH3I-1 is a Bcl-2 antagonist.
||PhiKan 083 is a carbazole derivative
||RO-5963 is a dual inhibitor of p53-MDM2 and p53-MDMX (IC50s: ~17 nM and ~24 nM, respectively).
||SJ-172550 is a small molecule inhibitor of MDMX (EC50: 5 μM).
||RITA(NSC 652287) induced cross-links of both DNA-DNA and DNA-protein with no detectable DNA single-strand breaks. RITA, like nutlin-3, can disrupt the p53/Mdm2 interaction.
||Tenovin-1 inhibits protein-deacetylating activities of SirT1 and SirT2 and protects against MDM2-mediated p53 degradation, which involves ubiquitination.
||Nutlin-3 is an MDM2 antagonist. Nutlin-3 inhibits the MDM2-p53 interaction (IC50: 0.09 μM) and activates p53. Antiproliferative agent; chemotherapeutic agent; induces apoptosis in
||SP 141 is a MDM2 inhibitor.SP-141 promotes MDM2 auto-ubiquitination and degradation, with anticancer activity.
||Triptolide is a diterpenes trioxide, immunosuppressive agent extracted from the Chinese herb Tripterygium wilfordii.
||Serdemetan is an orally bioavailable HDM2 antagonist with potential antineoplastic activity.
||Kevetrin hydrochloride is a small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity.
||RO8994 is a highly effective and specific inhibitor of spiroindolinone small-molecule MDM2, with IC50 of 20 nM (MTT proliferation assays) and 5 nM (HTRF binding assays).
||MX69 is the MDM2/XIAP inhibitor, blocking the MDM2 protein-XIAP RNA interaction, leading to MDM2 degradation.
||PK11007 is a p53 targeting compound, has anti-tumor activities through activation of unstable p53.
||Nutlin-3a, the active enantiomer of Nutlin-3, inhibits MDM2-p53 interactions and stabilizes the p53 protein.
||YH239-EE, the ethyl ester of YH239, is a potent p53-MDM2 antagonist and an apoptosis inducer.
||Idasanutlin (RG-7388) is an effective and specific p53-MDM2 inhibitor (IC50: 6 nM).
||MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.
||NSC 207895 suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.
||Nutlin-3b is a p53/MDM2 antagonist or inhibitor (IC50: 13.6 μM), 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nutlin-3a.
||RG7112 (RO5045337) is an orally bioavailable and selective p53-MDM2 inhibitor.
||Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway, it has anti-prostate cancer (PCA) activity that is mediated
||Ganoderic acid X
||Ganoderic acid X is a potential Mdm2 inhibitor(K(i) = 16nM). It is a potential anticancer drug, inhibits topoisomerases and induces apoptosis of cancer cells.
||VHD-valtrate has anticancer effects against human ovarian cancer cells in vitro and in vivo, it is a potential therapeutic agent for ovarian cancer, providing a basis for developme
||AMG 232 is a potent, selective and orally available inhibitor of p53-MDM2 interaction (IC50: 0.6 nM). It binds to MDM2 with a Kd of 0.045 nM.
||NVP-CGM097 is an effective and specific MDM2 inhibitor (IC50: 1.7 nM for hMDM2).